Constant dollars

Pressure BioSciences and Leading Cosmeceutical Innovator Dr. Denese SkinScience to Introduce Breakthrough UST Nanoemulsion Hair Regrowth Product in 2023

Dormant hair follicles should be more effectively revitalized by nutrients and therapeutics delivered quickly and powerfully via extremely fine droplet sizes produced from patented UST nanoemulsion technology

SOUTH EASTON, MA /ACCESSWIRE/October 26, 2022/ Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” or the “Company”), a leader in the development and sale of large-scale pressure-based instruments, consumables and specialty test services for cosmetics, nutraceuticals, biotherapy and food and beverage industries, among others, today confirmed specific product rollout plans agreed upon through their extensive partnership with the industry’s scientific leader in skincare, Dr. Denese SkinScience, which was recently shared in the FORCE Family Office sponsored Development of a new generation of skincare products webinar (PBIO/Dr. Denese FORCE Webinar 101322). Highlighting Dr. Denese’s world-renowned expertise and long-established leadership role as a skincare innovator, the webinar revealed that the two companies had chosen three additives/areas for their development. initial collaborative of valuable new skincare product lines, all of which would leverage PBI’s proprietary UST nanoemulsification process: (i) retinol, (ii) fat-soluble vitamin C and (iii) hair loss prevention/hair regrowth hair.

Dr. Adrienne Denese, MD, Ph.D. a globally recognized skincare visionary, anti-aging pioneer and President of Dr. Denese SkinScience, explained, “The central challenge of cosmeceuticals and skincare products skin is to deliver our scientifically designed payloads of critical nutritive and therapeutic ingredients in a rapid, complete, and precise manner while penetrating through the difficult resistive barrier of the skin to the living dermal tissues below. Many of these key ingredients are “oily” or lipophilic molecules that normally do not mix well with water, making them difficult to efficiently deliver for absorption by the water-based biochemistry of human bodies. of PBI’s industrially scalable UST platform for manufacturing nanoemulsions of extremely fine nanodroplet sizes, which are then stable and can deliver nutrime nts and therapeutic payloads with unprecedented efficiency, is without a doubt one of the most significant scientific and process breakthroughs for us r industry in my lifetime.”

Dr Denese continued: “From my patients and clients, the most requested addition to our product line is an effective intervention for hair loss and hair regeneration – and it is considered much more urgent. in age-related hair loss in women, beyond the huge demand among men.We believe that the challenge of truly effective stimulation and revitalization of weakened and dormant hair follicles will finally be overcome with the entry of PBI’s UST nanoemulsion platform technology, and we now plan to deliver an effective solution for this challenge.Within just a few weeks of making this decision, my team and I have made tremendous progress in the development of our very first line of hair loss prevention/hair restoration products. With the progress made to date, we now aim to launch the first products in this new line. Exciting array of products in time for the 2023 Christmas shopping season. What a gift that would be for our existing and loyal base of over 500,000 QV C customers and many more eager new buyers!”

Gary Smejkal, Senior Scientist at PBI, said, “We have also made wonderful progress lately in the development of UST-treated retinol and fat-soluble vitamin C. These very high quality nanoemulsions consist of oil droplets that are cohesive and extremely small. about 50 nanometers, they are much smaller than the wavelength of visible light, which makes them very transparent; they should also be stable and efficiently soluble in water. These initial nutrients and therapeutic nanoemulsion ingredients are expected to be available to Dr. Denese SkinScience for inclusion in their skincare products by mid-2023.”

Richard T. Schumacher, President and CEO of PBI, summarized the progress, “We believe that PBI’s nanoemulsified retinol UST and fat-soluble vitamin C enriched products will add valuable new dimensions to the multiple Dr. Denese SkinScience products at from mid 2023. More excitingly, it now looks like the new line of hair loss prevention/hair restoration products should be ready to go to market in about a year, which means these products could add millions in revenue to PBI’s results in 2023. This would be in addition to the approximately $5 million in revenue we expect will be received in 2023 from the completion of the three new nano-CBD contracts that were announced during months and which we expect to complete in 2023, with shipments commencing in the first quarter of next year.”

Mr. Schumacher concluded, “Dr. Adrienne Denese is a titan of the cosmeceutical/skincare industry worldwide and has amassed sales of over $500 million from QVC alone! Her life mission has been to help women look and feel younger and live healthier lives. has relentlessly focused on the science, quality, potency and efficacy of its products above all else. We feel extremely privileged to have won his support and close partnership between our businesses. These are indeed very exciting times for all PBIO stakeholders.

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly-enabling pressure-based solutions for global life sciences and other industries. Our products are based on the unique properties of constant hydrostatic (ie static) and alternating (ie pressure cycle technology or PCT) pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control biomolecular interactions in a safe and reproducible manner (eg, cell lysis, biomolecule extraction). Our primary focus is PCT-based product development for biomarker and target discovery, drug design and development, biotherapeutic characterization and quality control, soil and plant biology, forensics and anti-bioterrorism applications. In addition, major new market opportunities have arisen in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired patented technology from BaroFold, Inc. (the “BaroFold” technology ) to enable entry into the biopharmaceutical contract services industry, and (2) the use of our recently patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform for (i ) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and (ii) prepare high-quality, homogenized, low-acid, shelf-stable, or room-temperature-stable liquid foods that cannot be stored efficiently using existing non-thermal technologies.

Forward-looking statements

This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that could cause our actual results, levels of activity, performance or achievements or those of our industry are materially different from the results, future levels of activity, performance or achievements expressed, implied or inferred by such forward-looking statements. In some cases, you can identify forward-looking statements by words such as “may”, “will”, “should”, “could”, “should”, “expect”, “plan”, ” intends”, “anticipates”, “believes”, estimates”, “predicts”, “plans”, “potential” or “continues” or the negative form of these terms and other comparable terms. These statements are not only predictions based on our current expectations and projections of future events. You should not place undue reliance on these statements. When evaluating these statements, you should specifically consider various factors. Actual events or results may materially differ. These and other factors could cause our actual results to differ materially from any forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under “Risk factors” in the r Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021, and other reports filed by the Company from time to time with the latter. The Company undertakes no obligation to update the information contained in this press release, except as otherwise required by law.

For more information on PBI and this press release, please click on the following link:

Please visit us on Facebook, LinkedIn and Twitter.

Press contacts:

Richard T. Schumacher, President and CEO (508) 230-1828 (T)

John B. Hollister, Director of Sales and Marketing (805) 908-5719 (T)

Jeffrey N. Peterson, Chairman (650) 703-8557(T)

Adrienne Denese, MD, Ph.D., President of Dr. Denese SkinScience (888) 220-0303 (T)

THE SOURCE: Pressure BioSciences Inc.

See the source version on